Intranasal ketamine for acute cluster headache attacks—Results from a proof‐of‐concept open‐label trial

Objective To investigate the safety and efficacy of intranasal ketamine for the treatment of a single cluster headache (CH) attack. Background Acute treatment options for patients with CH who have an insufficient response to oxygen and triptans are limited. Intranasal ketamine has anecdotally been s...

Full description

Saved in:
Bibliographic Details
Published in:Headache 2022-01, Vol.62 (1), p.26-35
Main Authors: Petersen, Anja S., Pedersen, Adam S., Barloese, Mads C. J., Holm, Per, Pedersen, Ole, Jensen, Rigmor H., Snoer, Agneta H.
Format: Article
Language:English
Subjects:
acute treatment
Administration, Intranasal
Adult
Analgesics - administration & dosage
Analgesics - adverse effects
Analgesics - pharmacology
chronic cluster headache
Chronic Disease
Cluster Headache - drug therapy
Clusters
Confidence intervals
Drug abuse
Female
Headache
Headaches
Humans
Ketamine
Ketamine - administration & dosage
Ketamine - adverse effects
Ketamine - pharmacology
Male
Middle Aged
Migraine
open label
Oxygen
Pain
Patients
Physicians
Pilot Projects
Proof of Concept Study
Sumatriptan
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To investigate the safety and efficacy of intranasal ketamine for the treatment of a single cluster headache (CH) attack. Background Acute treatment options for patients with CH who have an insufficient response to oxygen and triptans are limited. Intranasal ketamine has anecdotally been successful in treating a CH attack. Methods We conducted an open‐label pilot study enrolling 23 patients with chronic CH (International Classification of Headache Disorders, 3rd edition), and of these, 20 patients treated a single CH attack with intranasal ketamine. Under in‐hospital observation, patients received 15 mg of intranasal ketamine every 6 min a maximum of five times. The primary endpoint was a 50% reduction in pain intensity within 15 min after initiating treatment. Results The primary endpoint was not met; 15 min after the first ketamine administration, the mean reduction in pain intensity was 1.1 (95% confidence interval [CI]: −0.6 to 2.7, p = 0.188) on the numeric rating scale (NRS), equivalent to a 15% reduction in pain intensity. However, 30 min after the first application, the pain intensity was reduced by 59% on an 11‐point NRS (mean difference: 4.3, 95% CI: 2.4–6.2, p 
ISSN:0017-8748
1526-4610
DOI:10.1111/head.14220